Uptrend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Aug 7 · inside the Ichimoku cloud · RSI 51 · MACD above its signal
None of the 29 investors followed here reported a position in RHHVF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RHHVF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for RHHVF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.3 | 8.3 | -22.8 | 10.3 | 3.5 | -2.1 | 6.1 | -2.4 | -3.3 | 5.6 | +6.1% | ||
| 2025 | 11.8 | 5.2 | -0.8 | -0.5 | -0.5 | 0.4 | -2.4 | 2.8 | 1.4 | -1.7 | 18.1 | 7.8 | +47.5% |
| 2024 | -0.5 | -8.1 | -1.7 | -6.8 | 4.0 | 11.6 | 15.8 | 4.7 | -5.3 | -3.2 | -6.6 | -2.7 | −1.8% |
| 2023 | 0.6 | -6.6 | -3.3 | 11.0 | -0.1 | -2.6 | 1.4 | -4.5 | -7.0 | -5.1 | 1.6 | 7.5 | −8.5% |
| 2022 | -4.9 | -1.2 | 4.7 | -5.7 | -10.4 | -2.2 | 0.9 | -2.8 | -2.4 | 4.8 | -1.0 | -5.0 | −23.3% |
| 2021 | 0.6 | -3.5 | -0.7 | 0.5 | 3.7 | 8.5 | 5.4 | 4.0 | -9.6 | 5.1 | 0.3 | 5.5 | +19.8% |
| 2020 | 2.4 | -1.6 | -1.1 | 7.2 | 0.5 | -0.8 | -0.5 | 2.2 | -1.7 | -7.4 | 2.9 | 3.4 | +4.8% |
| 2019 | 6.3 | 5.0 | -1.3 | -4.0 | 0.2 | 6.4 | -5.0 | 3.2 | 5.9 | 3.0 | 2.7 | 5.3 | +30.4% |
| 2018 | -2.3 | -4.8 | -2.4 | -1.7 | -4.9 | 4.3 | 9.7 | 1.6 | -1.3 | -1.4 | 7.0 | -3.9 | −1.2% |
| 2017 | 4.0 | 2.6 | 5.2 | 1.8 | 5.1 | -7.8 | 0.1 | -0.3 | 1.0 | -9.4 | 9.2 | -0.3 | +10.1% |
| 2016 | -5.4 | -1.0 | -3.3 | 1.6 | 3.2 | 0.7 | -2.6 | -4.9 | 2.3 | -7.8 | -3.1 | 2.8 | −16.8% |
| 2015 | -0.2 | 0.3 | 1.4 | 3.9 | 7.0 | -7.9 | 3.1 | -6.2 | -2.9 | 3.2 | -1.8 | 2.4 | +1.1% |
| 2014 | -2.1 | 11.1 | -1.8 | -2.5 | 0.7 | 0.8 | -2.4 | 0.4 | 1.1 | -0.5 | 1.3 | -9.0 | −3.8% |
| 2013 | 11.1 | 3.3 | 1.7 | 7.1 | -0.9 | 0.5 | -1.4 | 1.8 | 8.2 | 2.5 | 0.9 | 0.7 | +40.8% |
| 2012 | 0.9 | 1.3 | 0.9 | 4.5 | -14.3 | 9.8 | 2.7 | 1.7 | 5.5 | 1.9 | 1.6 | 2.0 | +18.0% |
| 2011 | 4.8 | -2.0 | -4.5 | 13.1 | 8.0 | -4.9 | 8.0 | -2.7 | -8.0 | 2.2 | -4.2 | 7.3 | +15.7% |
| 2010 | -0.3 | -1.9 | -2.2 | -2.7 | -12.6 | 0.4 | -6.0 | 4.4 | 1.1 | 8.4 | -6.9 | 6.0 | −13.3% |
| 2009 | 15.4 | -3.8 | 4.2 | 3.8 | 10.1 | 5.7 | 1.6 | 0.1 | 3.8 | 1.0 | +48.9% |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Buy / hold / sell counts